Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
about
Phytochemicals for the Management of MelanomaPathways and therapeutic targets in melanomaBeyond BRAF: where next for melanoma therapy?Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated ProteinsCIViC databaseMetformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.Mutant HRAS as novel target for MEK and mTOR inhibitorsPrimary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockadeTargeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.The phosphoinositide 3-kinase pathway and therapy resistance in cancerPI3K and cancer: lessons, challenges and opportunitiesCombination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancerMicroRNA-1301 inhibits proliferation of human glioma cells by directly targeting N-Ras.Epidermal Growth Factor Receptor Cell Proliferation Signaling PathwaysTreatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to dateMolecular therapy for acute myeloid leukaemia.Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia.Melanoma: clinical features and genomic insights.MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-RasMiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.Genotyping of cutaneous melanoma.A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cellsRSK1 activation promotes invasion in nodular melanoma.Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.SDF-1/CXCL12 induces directional cell migration and spontaneous metastasis via a CXCR4/Gαi/mTORC1 axis.Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancerEmpirical inference of circuitry and plasticity in a kinase signaling networkCombined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgraftsCombined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle.Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth.MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.miR-98 functions as a tumor suppressor in salivary adenoid cystic carcinomasTargeting mutant NRAS signaling pathways in melanoma.Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cellsRationale-based therapeutic combinations with PI3K inhibitors in cancer treatmentSearching for the Chokehold of NRAS Mutant Melanoma.Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
P2860
Q26766708-EA7C7AD0-9048-4DA7-A627-90F5D1B07DEAQ26865736-DC952A6D-C1BF-4801-92EA-CE0D171ED7E6Q27006853-14F14036-CAE9-46E3-B73F-D6C334034676Q27027458-7DF7C26B-A716-4310-9CFC-2659509184FEQ27612411-24280E10-EDA4-4F23-9838-0264BDBDF0F1Q27853104-2FB8770F-F5B2-4A33-BF3D-57BCA4BF4171Q27853238-FBE07A2F-479A-4E44-8BC1-63FD96BD5A83Q27853295-A97AF72D-A029-48F8-87E6-5B0DA5CD4EE9Q27853330-5F0D86D2-F9D2-4D4B-AD89-38787833B623Q28082811-56EBB1F7-B5C3-4AAF-9B19-1DD30776FFBDQ30080017-A7CF3B53-39C5-447B-8AF8-250165BE0CB2Q30557008-9EF9D975-C8E5-4CE3-ADAD-9C09D88F27E0Q33622710-F1345CDC-E262-454F-B575-D3C22CD6A204Q33737298-A03435BD-B176-4B75-84E5-22FF68F350E9Q33887664-07DECBC6-F3DE-49D9-B6D5-3B711C0CA333Q33925672-53D36693-B6D0-4543-9CCB-7C52BC504AD6Q34052520-1AE0AE70-E20B-4CE0-B0EB-7AC5A47B7EF8Q34083191-1D044596-C3AD-488C-80FF-BA325C246FACQ34193764-6DB9EDA5-15D2-44B4-B780-0AE2E6436C12Q34221882-0B4E5EAF-0E3A-44A4-BB2F-E6C0C817C28CQ34365949-4ED11F26-0A43-4F3B-A5D3-F6525F80E189Q34667738-6CB66927-C5D0-40D9-85C2-8CAE91A2E2E0Q34818301-79942215-25AC-43DA-801E-B989B216EE35Q35043887-BF583382-B33B-41AA-BADE-9C276B7DFA22Q35143744-DC0B22BB-48A8-4972-9F30-348F9DAB67BEQ35262625-EC33A7B4-4E41-43DA-9F82-C2C8DF0EC28FQ35576488-9548818F-9647-4112-8480-6D8FF10DDA97Q35657842-323B06EA-E6F5-4042-A659-11166C9DD191Q35796180-AC25DC7F-FDAF-4002-94E8-01CA122997CFQ35798540-C60FCD8B-A00D-41D0-A2BC-B48AF7D735AFQ36054290-D46DA671-88D4-426D-B91D-7E353AB38B73Q36219160-8D1A651C-532E-4407-ADE5-820E5696CB45Q36429062-9D22D8E7-D705-49C9-849B-2AAB50B36BD7Q36682132-62D26926-5DEE-4E18-8D64-E9124A3E4381Q36733552-601FE3D1-0DC2-4C2B-8811-73287DBC4678Q36902066-F1C92E08-E9FF-48E7-8EE7-BEBF3070F048Q36916468-66B0CCB4-175F-47F5-9CF6-504DA66557B8Q36997524-91E941AE-2CFD-485F-950C-7BBF32DCC3D8Q37038604-D136A8AC-A560-496A-8BD7-1E5A5C29A7F5Q37093269-FEAC42C5-2286-49A5-B8C7-75DDBCFBB7D8
P2860
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Combined targeting of MEK and ...... melanoma in vitro and in vivo.
@ast
Combined targeting of MEK and ...... melanoma in vitro and in vivo.
@en
Combined targeting of MEK and ...... melanoma in vitro and in vivo.
@nl
type
label
Combined targeting of MEK and ...... melanoma in vitro and in vivo.
@ast
Combined targeting of MEK and ...... melanoma in vitro and in vivo.
@en
Combined targeting of MEK and ...... melanoma in vitro and in vivo.
@nl
altLabel
Combined targeting of MEK and ...... melanoma in vitro and in vivo
@en
prefLabel
Combined targeting of MEK and ...... melanoma in vitro and in vivo.
@ast
Combined targeting of MEK and ...... melanoma in vitro and in vivo.
@en
Combined targeting of MEK and ...... melanoma in vitro and in vivo.
@nl
P2093
P2860
P3181
P356
P1476
Combined targeting of MEK and ...... melanoma in vitro and in vivo.
@en
P2093
Adil I Daud
Anoosheh Ebaee
Christian Posch
Gary A Green
Homayoun Moslehi
Luzviminda Feeney
Michelle T Dimon
Philip E LeBoit
P2860
P304
P3181
P356
10.1073/PNAS.1216013110
P407
P577
2013-03-05T00:00:00Z